Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Bioheart Inc. (USRM : OTC)
 
 • Company Description   
U.S. Stem cell, Inc. is engaged in the regenerative medicine / cellular therapy industry. The company focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. Its operating division consists of US Stem Cell Training, Vetbiologics and US Stem Cell Clinic. US Stem Cell, Inc., formerly known as Bioheart, Inc., is headquartered in Sunrise, Florida.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.01 Daily Weekly Monthly
20 Day Moving Average: 496,667 shares
Shares Outstanding: 595.60 (millions)
Market Capitalization: $3.99 (millions)
Beta: -0.58
52 Week High: $0.03
52 Week Low: $0.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.94% 1.89%
12 Week -21.18% -11.41%
Year To Date 11.67% 36.42%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1560 SAWGRASS CORPORATE PKWY 4TH FLOOR
-
SUNRISE,FL 33323
USA
ph: 954-835-1500
fax: 954-845-9976
rmadaris@bioheartinc.com http://www.us-stemcell.com
 
 • General Corporate Information   
Officers
Mike Tomas - Chief Executive Officer; Chief Financial Officer
Mark P. Borman - Chairman of the Board
William P. Murphy Jr - Director; Chairman Emeritus
Sheldon Anderson - Director
Greg Knutson - Director

Peer Information
Bioheart Inc. (CORR.)
Bioheart Inc. (RSPI)
Bioheart Inc. (CGXP)
Bioheart Inc. (BGEN)
Bioheart Inc. (GTBP)
Bioheart Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 90350U100
SIC: 8731
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 07/15/22
Share - Related Items
Shares Outstanding: 595.60
Most Recent Split Date: 11.00 (0.00:1)
Beta: -0.58
Market Capitalization: $3.99 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 19.97
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -79.27%
vs. Previous Quarter: -58.17%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -1,353.11
09/30/21 - -1,283.06
Current Ratio
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.01
Quick Ratio
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.01
Operating Margin
03/31/22 - -
12/31/21 - -1,644.78
09/30/21 - -1,112.03
Net Margin
03/31/22 - -
12/31/21 - -1,644.78
09/30/21 - -1,112.03
Pre-Tax Margin
03/31/22 - -
12/31/21 - -1,635.32
09/30/21 - -1,111.68
Book Value
03/31/22 - -
12/31/21 - -0.03
09/30/21 - -0.03
Inventory Turnover
03/31/22 - -
12/31/21 - 19.70
09/30/21 - 13.85
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©